Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIAD 7 trial of CYT107 in lymphopenic hospitalized COVID-19 patients
ISRCTN15913068Phase 2Completed
- Sponsor
- RevImmune
- Start
- May 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CYT107 with Placebo (2 arms). Primary endpoint: Absolute lymphocyte count. Started May 2020; status: completed.
02
Drugs
recombinant human interleukin-7
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN15913068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15913068.